Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 13.3 mg/24 h (Luye Pharma AG, Germany) and the marketed Reference product Exelon® 13.3 mg/24 h transdermales Pflaster (Novartis Pharma GmbH, Germany) after multiple patch applications. Each of both treatments will last for 11 days with a washout period of 14 days between the treatments.
Epistemonikos ID: d33812a303d47d3b8c0b41fdcb3ba4fa80906afc
First added on: Oct 02, 2023